Product Name: MK-0822

4 trials

Sponsors

MERCK SHARP & DOHME CORP., Merck Sharp & DOhme (Sweden) AB, Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Conditions

Osteoporosis MedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalPostmenopausal Osteoporosis MedDRA version: 14.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal Osteoporosis MedDRA version: 17.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disorderslow BMD (bone mineral density) MedDRA version: 9.1 Level: LLT Classification code 10032364 Term: Other osteoporosis

Phase 2

Estudio en fase IIa aleatorizado, doble ciego, controlado con placebo para evaluar los efectos de odanacatib (MK-0822) sobre la densidad mineral ósea (DMO) y la seguridad general en el tratamiento de la osteoporosis en mujeres posmenopáusicas previamente tratadas con alendronato A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate - Odanacatib

Active, not recruitingEUCTR2008-008257-30-ES

Merck & Co., Inc.Osteoporosis MedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal

Start: 2009-03-31Target: 160Updated: 2019-06-30

Phase 3

A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Active, not recruitingEUCTR2011-005514-10-LT

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Postmenopausal Osteoporosis MedDRA version: 17.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Start: 2012-03-14Target: 8254Updated: 2017-02-20

Unknown Phase

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Active, not recruitingEUCTR2007-002693-66-LT

MERCK SHARP & DOHME CORP.Postmenopausal Osteoporosis MedDRA version: 14.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Start: 2007-11-13Target: 16300Updated: 2013-01-07

A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on Bone Micro-architecture in Postmenopausal Women Treated with Vitamin D

Active, not recruitingEUCTR2008-004504-31-SE

Merck Sharp & DOhme (Sweden) ABlow BMD (bone mineral density) MedDRA version: 9.1 Level: LLT Classification code 10032364 Term: Other osteoporosis

Start: 2008-09-16Target: 180Updated: 2012-05-15

Related Papers

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial

Journal of Bone and Mineral Research2020-12-0126 citations